GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Home
/
insight
/
details

Innovative Therapeutic Approaches: Chimeric Antigen Receptor (CAR) T Cells in Autoimmune Disease Management

NextEdge Admin

22 Apr 2024

3 min 59 sec

Autoimmune diseases represent a diverse group of disorders characterized by a breakdown in immune tolerance, leading to an aberrant immune response against the body’s own tissues. This breach of tolerance results in the activation of autoreactive T cells and B cells, accompanied by the production of autoantibodies, collectively contributing to organ damage. Disorders such as rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, pemphigus, and multiple sclerosis fall under this umbrella of autoimmune conditions.

The pathogenesis of autoimmune diseases involves a complex interplay of genetic, environmental, and immunological factors. Genetic predisposition plays a significant role, with certain individuals being genetically susceptible to developing autoimmune disorders.

In the context of autoimmune diseases, autoreactive B cells play a pivotal role in the perpetuation of the immune response. These B cells give rise to autoantibodies that target the body’s own antigens, contributing to the formation of immune complexes. These immune complexes can deposit in various tissues, leading to inflammation and tissue damage. Autoantibodies can also directly contribute to tissue damage by activating complement pathways or binding to cell surfaces.

One commonly targeted approach in autoimmune disease management is the depletion of B cells. However, current therapies, such as rituximab, often face limitations. These limitations arise from the persistence of autoreactive B cells in lymphatic organs and inflamed tissues, contributing to suboptimal therapeutic efficacy.

In response to these challenges, researchers have explored innovative therapeutic strategies, including the use of chimeric antigen receptor (CAR) T cells. Originally successful in the treatment of B-cell malignancies, CAR T cells have been adapted to target autoreactive B cells in autoimmune diseases. Specifically, CAR T cells engineered to recognize the CD19 antigen have demonstrated remarkable success in refractory systemic lupus erythematosus and dermatomyositis. The principle involves the adoptive transfer of T cells that have been genetically modified to express CARs, enabling them to target and eliminate CD19-expressing B cells selectively.

This approach achieves a rapid and sustained depletion of circulating B cells, resulting in both clinical and serological remission. The emphasis on targeting specific antigens, such as CD19, enhances the precision of therapy, minimizing off-target effects and potentially offering a more effective and tailored treatment for autoimmune diseases.

As research in this field progresses, the evolving strategies utilizing CAR T cells for targeted therapy hold promise in reshaping the landscape of autoimmune disease management, addressing the underlying pathogenic mechanisms, and providing new avenues for achieving lasting immune modulation.